Hosted on MSN17d
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
The New York Times18d
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...
FierceBiotech18d
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse ...
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.
24/7 Wall St7d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Novo Nordisk has announced a new partnership with Variant Bio to help develop new medicines for metabolic diseases. The company aims to utilize Variant Bio’s genetic analysis platform to ...